Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature

References

• International Agency for Research on CancerGLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012Lyon, FranceInternational Agency for Research on Cancer2012 Available from: http://globocan.iarc.frAccessed November 10, 2014
   Google Scholar
• ErdmannFLortet-TieulentJSchüzJInternational trends in the incidence of malignant melanoma 1953–2008 – are recent generations at higher or lower risk?Int J Cancer2013132238540022532371
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardECancer statistics, 2006CA Cancer J Clin200656210613016514137
   PubMed Web of Science ®Google Scholar
• ForseaAMDel MarmolVde VriesEBaileyEEGellerACMelanoma incidence and mortality in Europe: new estimates, persistent disparitiesBr J Dermatol201216751124113022759278
   PubMed Web of Science ®Google Scholar
• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2008Bethesda, MDNational Cancer Institute2011
   Google Scholar
• De AngelisRSantMColemanMPEUROCARE-5 Working GroupCancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based studyLancet Oncol201415233424314615
   PubMed Web of Science ®Google Scholar
• BerrinoFDe AngelisRSantMSurvival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: results of the EUROCARE-4 studyLancet Oncol20078977378317714991
   PubMed Web of Science ®Google Scholar
• SantMAllemaniCSantaquilaniMEUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentaryEur J Cancer200945693199119171476
   PubMed Web of Science ®Google Scholar
• CrocettiEMalloneSRobsahmTESurvival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 studyEur J Cancer Epub952015
   Web of Science ®Google Scholar
• EggermontAMChiarion-SileniVGrobJJAdjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialLancet Oncol201516552253025840693
   PubMed Web of Science ®Google Scholar
• GuidaMPiscontiSColucciGMetastatic melanoma: the new era of targeted therapyExpert Opin Ther Targets201216Suppl 2S61S7022443134
   PubMed Web of Science ®Google Scholar
• SchadendorfDHodiFSRobertCPooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanomaJ Clin Oncol201533171889189425667295
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• FDA Approves Second PD-1 InhibitorNivolumab, for MelanomaDepartment of Health and Human Services. FDA U.S. Food and Drug Administration Available from: http://www.cancernetwork.com/melanoma/fda-approves-second-pd-1-inhibitor-nivolumab-melanomaAccessed March 16, 2016
   Google Scholar
• Trametinib and DabrafenibDepartment of Health and Human Services. FDA U.S. Food and Drug Administration Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381451.htmAccessed March 16, 2016
   Google Scholar
• FeinsteinARSosinDMWellsCKThe Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancerN Engl J Med198531225160416084000199
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATezlaffJAltman DG; PRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med20096e10000097
   Web of Science ®Google Scholar
• EisemannNJansenLHolleczekBUp-to-date results on survival of patients with melanoma in GermanyBr J Dermatol2012167360661222564081
   PubMed Web of Science ®Google Scholar
• ErikssonHLythJMansson-BrahmeELow level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in SwedenEur J Cancer201349122705271623583439
   PubMed Web of Science ®Google Scholar
• de WaalACAbenKKvan RossumMMKiemeneyLAMelanoma of unknown primary origin: a population-based study in the NetherlandsEur J Cancer201349367668323031553
   PubMed Web of Science ®Google Scholar
• HancockBWWheatleyKHarrisSAdjuvant interferon in high-risk melanoma: the AIM HIGH Study – United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanomaJ Clin Oncol2004221536114665609
   PubMed Web of Science ®Google Scholar
• KleebergURSuciuSBrockerEBFinal results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-α2b versus rIFN-γ versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasisEur J Cancer200440339040214746858
   PubMed Web of Science ®Google Scholar
• EggermontAMSuciuSMacKieRPost-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialLancet200536694921189119616198768
   PubMed Web of Science ®Google Scholar
• GarbeCRadnyPLinseRAdjuvant low-dose interferon {α}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasisAnn Oncol20081961195120118281266
   PubMed Web of Science ®Google Scholar
• EggermontAMSuciuSTestoriALong-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaJ Clin Oncol201230313810381823008300
   PubMed Web of Science ®Google Scholar
• HanssonJAamdalSBastholtLTwo different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trialLancet Oncol201112214415221256809
   PubMed Web of Science ®Google Scholar
• GillgrenPDrzewieckiKTNiinM2 cm versus 4 cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trialLancet201137898031635164222027547
   PubMed Web of Science ®Google Scholar
• KoskivuoIHernbergMVihinenPSentinel lymph node biopsy and survival in elderly patients with cutaneous melanomaBr J Surg201198101400140721638276
   PubMed Web of Science ®Google Scholar
• DebarbieuxSDuruGDalleSBeatrixOBalmeBThomasLSentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissectionBr J Dermatol20071571586717501957
   PubMed Web of Science ®Google Scholar
• KunteCGeimerTBaumertJPrognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1,049 patients with cutaneous melanomaMelanoma Res201020433033720526218
   PubMed Web of Science ®Google Scholar
• HohnheiserAMGefellerOGohlJSchulerGHohenbergerWMerkelSMalignant melanoma of the skin: long-term follow-up and time to first recurrenceWorld J Surg201135358058921125274
   PubMed Web of Science ®Google Scholar
• MeierASatzgerIVolkerBKappAGutzmerRComparison of classification systems in melanoma sentinel lymph nodes – an analysis of 697 patients from a single centerCancer2010116133178318820564647
   PubMed Web of Science ®Google Scholar
• CascinelliNBombardieriEBufalinoRSentinel and non-sentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survivalJ Clin Oncol200624274464447116983115
   PubMed Web of Science ®Google Scholar
• MandalaMImbertiGLPiazzalungaDClinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected databaseEur J Cancer200945142537234519553103
   PubMed Web of Science ®Google Scholar
• TestoriADe SalvoGLMontescoMCClinical considerations on sentinel node biopsy in melanoma from an Italian multi-centric study on 1,313 patients (SOLISM-IMI)Ann Surg Oncol20091672018202719132446
   PubMed Web of Science ®Google Scholar
• QuaglinoPMarencoFOsella-AbateSVitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort studyAnn Oncol201021240941419622589
   PubMed Web of Science ®Google Scholar
• MandalàMImbertiGLPiazzalungaDAssociation of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanomaMayo Clin Proc201186211311921282485
   PubMed Web of Science ®Google Scholar
• NoweckiZIRutkowskiPNasierowska-GuttmejerARukaWSurvival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanomaAnn Surg Oncol200613121655166317016755
   PubMed Web of Science ®Google Scholar
• RutkowskiPNoweckiZIDziewirskiWMelanoma without a detectable primary site with metastases to lymph nodesDermatol Surg201036686887620482725
   PubMed Web of Science ®Google Scholar
• de VriesMSpeijersMJBastiaannetELong-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanomaEur J Surg Oncol201137868168721636244
   PubMed Web of Science ®Google Scholar
• KettlewellSMoyesCBrayCValue of sentinel node status as a prognostic factor in melanoma: prospective observational studyBMJ20063327555142316735303
   PubMed Web of Science ®Google Scholar
• PlymAUllenhagGJBreivaldMLambeMBerglundAClinical characteristics, management and survival in young adults diagnosed with malignant melanoma: a population-based cohort studyActa Oncol201453568869624369746
   PubMed Web of Science ®Google Scholar
• BayCKejsAStormHEngholmGIncidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish Populational-based Register Study 1989–2011Cancer Epidemiol2015391725468643
   PubMed Web of Science ®Google Scholar
• de VriesEBrayFIEggermontAMCoeberghJWEuropean Network of Cancer RegistriesMonitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristicsEur J Cancer Prev200413538739515452451
   PubMed Web of Science ®Google Scholar
• StormHHMichelsenEVClemmensenIHPihlJThe Danish Cancer Registry – history, content, quality and useDan Med Bull19974455355399408738
   PubMed Web of Science ®Google Scholar